

Allison Carol Nugent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8411240/publications.pdf>

Version: 2024-02-01

87
papers

8,503
citations

66343

42
h-index

54911

84
g-index

89
all docs

89
docs citations

89
times ranked

11864
citing authors

#	ARTICLE	IF	CITATIONS
1	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the <sc>ENIGMA</sc> Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 56-82.	3.6	67
2	On-scalp magnetocortigraphy with optically pumped magnetometers: Simulated performance in resolving simultaneous sources. <i>NeuroImage Reports</i> , 2022, 2, 100093.	1.0	12
3	Magnetoencephalography biomarkers of suicide attempt history and antidepressant response to ketamine in treatment-resistant major depression. <i>Journal of Affective Disorders</i> , 2022, 312, 188-197.	4.1	3
4	Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. <i>Molecular Psychiatry</i> , 2021, 26, 3292-3301.	7.9	57
5	Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2021, 279, 239-249.	4.1	7
6	Magnetoencephalography Studies in Mood Disorders. , 2021, , 192-205.		0
7	Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 673159.	2.6	9
8	Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 354-363.	1.5	12
9	Multilayer MEG functional connectivity as a potential marker for suicidal thoughts in major depressive disorder. <i>NeuroImage: Clinical</i> , 2020, 28, 102378.	2.7	15
10	The Effect of Ketamine on Electrophysiological Connectivity in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 519.	2.6	15
11	Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment. <i>Neuropsychopharmacology</i> , 2020, 45, 982-989.	5.4	37
12	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. <i>Neuropsychopharmacology</i> , 2020, 45, 1398-1404.	5.4	47
13	Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder. <i>Human Brain Mapping</i> , 2019, 40, 3940-3950.	3.6	36
14	Mapping anticipatory anhedonia: an fMRI study. <i>Brain Imaging and Behavior</i> , 2019, 13, 1624-1634.	2.1	8
15	Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 610-618.	1.5	26
16	Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues. <i>BMC Psychiatry</i> , 2019, 19, 332.	2.6	24
17	Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 10-18.	2.1	27
18	Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 283, 64-66.	1.8	34

#	ARTICLE	IF	CITATIONS
19	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. <i>Molecular Psychiatry</i> , 2019, 24, 1040-1052.	7.9	187
20	Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration. <i>Biological Psychiatry</i> , 2018, 84, 582-590.	1.3	123
21	7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study. <i>Neuropsychopharmacology</i> , 2018, 43, 1908-1914.	5.4	38
22	Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. <i>NeuroImage: Clinical</i> , 2018, 20, 92-101.	2.7	51
23	Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. <i>Biological Psychiatry</i> , 2017, 81, 886-897.	1.3	334
24	Novel genetic loci associated with hippocampal volume. <i>Nature Communications</i> , 2017, 8, 13624.	12.8	250
25	Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 549-551.	1.5	0
26	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2017, 31, 1570-1577.	4.0	17
27	Altered interaction with environmental reinforcers in major depressive disorder: Relationship to anhedonia. <i>Behaviour Research and Therapy</i> , 2017, 97, 170-177.	3.1	8
28	Active suicidal ideation during clinical antidepressant trials. <i>Psychiatry Research</i> , 2017, 257, 303-308.	3.3	9
29	The Ethics of Clinical Trials Research in Severe Mood Disorders. <i>Bioethics</i> , 2017, 31, 443-453.	1.4	10
30	Deriving frequency-dependent spatial patterns in MEG-derived resting state sensorimotor network: A novel multiband ICA technique. <i>Human Brain Mapping</i> , 2017, 38, 779-791.	3.6	11
31	Neuroimaging Promises and Caveats. , 2016, , .		0
32	Novel genetic loci underlying human intracranial volume identified through genome-wide association. <i>Nature Neuroscience</i> , 2016, 19, 1569-1582.	14.8	213
33	Amygdala response to explicit sad face stimuli at baseline predicts antidepressant treatment response to scopolamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 67-73.	1.8	32
34	Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2016, 254, 56-66.	1.8	35
35	Reliability of 7T ¹ H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 88-98.	3.4	35
36	Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health. <i>Lancet Psychiatry</i> , the, 2016, 3, 436-442.	7.4	11

#	ARTICLE	IF	CITATIONS
37	Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder. <i>NeuroImage</i> , 2015, 118, 1-12.	4.2	103
38	Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv028-pyv028.	2.1	14
39	The Relationship between Glucose Metabolism, Resting-State fMRI BOLD Signal, and GABA _A -Binding Potential: A Preliminary Study in Healthy Subjects and Those with Temporal Lobe Epilepsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 583-591.	4.3	104
40	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , 2015, 520, 224-229.	27.8	772
41	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 97-114.	2.5	169
42	Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography. <i>Acta Neuropsychiatrica</i> , 2015, 27, 143-152.	2.1	28
43	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , 2015, 29, 596-607.	4.0	175
44	Neural Correlates of Suicidal Ideation and Its Reduction in Depression. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu069-pyu069.	2.1	46
45	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. <i>Journal of Affective Disorders</i> , 2015, 172, 307-311.	4.1	27
46	Biomarkers in mood disorders research: developing new and improved therapeutics. <i>Revista De Psiquiatria Clinica</i> , 2014, 41, 131-134.	0.6	11
47	Cerebrospinal Fluid Monocyte Chemoattractant Protein-1 in Alcoholics: Support for a Neuroinflammatory Model of Chronic Alcoholism. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1301-1306.	2.4	33
48	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 119-128.	1.9	74
49	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. <i>Depression and Anxiety</i> , 2014, 31, 297-307.	4.1	43
50	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. <i>Brain Imaging and Behavior</i> , 2014, 8, 153-182.	2.1	696
51	Automated subcortical segmentation using FIRST: Test-retest reliability, interscanner reliability, and comparison to manual segmentation. <i>Human Brain Mapping</i> , 2013, 34, 2313-2329.	3.6	98
52	Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression. <i>European Neuropsychopharmacology</i> , 2013, 23, 822-829.	0.7	30
53	Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [18F]fluorodeoxyglucose positron emission tomography study. <i>NeuroImage: Clinical</i> , 2013, 2, 341-355.	2.7	3
54	Reduced thalamic volumes in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2013, 213, 179-185.	1.8	79

#	ARTICLE	IF	CITATIONS
55	Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2013, 73, 1213-1221.	1.3	139
56	DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 2095-2101.	2.1	51
57	Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. <i>Journal of Psychopharmacology</i> , 2013, 27, 894-902.	4.0	24
58	The Functional DRD3 Ser9Gly Polymorphism (rs6280) Is Pleiotropic, Affecting Reward as Well as Movement. <i>PLoS ONE</i> , 2013, 8, e54108.	2.5	60
59	Effects of arterial cannulation stress on regional cerebral blood flow in major depressive disorder. <i>Scientific Reports</i> , 2012, 2, 308.	3.3	4
60	Identification of common variants associated with human hippocampal and intracranial volumes. <i>Nature Genetics</i> , 2012, 44, 552-561.	21.4	594
61	Baseline mood-state measures as predictors of antidepressant response to scopolamine. <i>Psychiatry Research</i> , 2012, 196, 62-67.	3.3	28
62	Association between subcortical volumes and verbal memory in unmedicated depressed patients and healthy controls. <i>Neuropsychologia</i> , 2012, 50, 2348-2355.	1.6	29
63	Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. <i>Bipolar Disorders</i> , 2012, 14, 135-145.	1.9	243
64	Habenula Volume in Bipolar Disorder and Major Depressive Disorder: A High-Resolution Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2011, 69, 336-343.	1.3	159
65	Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. <i>NeuroImage</i> , 2011, 54, 2643-2651.	4.2	170
66	Sex differences in the neural correlates of autonomic arousal: A pilot PET study. <i>International Journal of Psychophysiology</i> , 2011, 80, 182-191.	1.0	63
67	Lateralization and gender differences in the dopaminergic response to unpredictable reward in the human ventral striatum. <i>European Journal of Neuroscience</i> , 2011, 33, 1706-1715.	2.6	82
68	Heart rate variability during motor and cognitive tasks in females with major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 1-8.	1.8	49
69	Habenula volume in post-traumatic stress disorder measured with high-resolution MRI. <i>Biology of Mood & Anxiety Disorders</i> , 2011, 1, 7.	4.7	32
70	Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 545-551.	2.1	23
71	Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: The impact of medication. <i>NeuroImage</i> , 2010, 49, 2966-2976.	4.2	103
72	The Effects of Tryptophan Depletion on Neural Responses to Emotional Words in Remitted Depression. <i>Biological Psychiatry</i> , 2009, 66, 441-450.	1.3	108

#	ARTICLE	IF	CITATIONS
73	Bcl-2 Polymorphism Influences Gray Matter Volume in the Ventral Striatum in Healthy Humans. <i>Biological Psychiatry</i> , 2009, 66, 804-807.	1.3	24
74	Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion. <i>NeuroImage</i> , 2008, 43, 764-774.	4.2	16
75	Altered Cerebral $\text{[}^3\text{H}\text{]}$ -Aminobutyric Acid Type A α Benzodiazepine Receptor Binding in Panic Disorder Determined by $\text{[}^{11}\text{C}\text{]}$ Flumazenil Positron Emission Tomography. <i>Archives of General Psychiatry</i> , 2008, 65, 1166.	12.3	103
76	Reduced Posterior Hippocampal Volume in Posttraumatic Stress Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1087-1091.	2.2	121
77	Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. <i>NeuroImage</i> , 2006, 30, 485-497.	4.2	191
78	Serotonin Transporter Binding in Bipolar Disorder Assessed using $\text{[}^{11}\text{C}\text{]}$ DASB and Positron Emission Tomography. <i>Biological Psychiatry</i> , 2006, 60, 207-217.	1.3	183
79	Reduced Muscarinic Type 2 Receptor Binding in Subjects With Bipolar Disorder. <i>Archives of General Psychiatry</i> , 2006, 63, 741.	12.3	106
80	Differential Effects of 5-HTTLPR Genotypes on the Behavioral and Neural Responses to Tryptophan Depletion in Patients With Major Depression and Controls. <i>Archives of General Psychiatry</i> , 2006, 63, 978.	12.3	140
81	No Change in Serotonin Type 1A Receptor Binding in Patients With Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 383-385.	7.2	70
82	Frontotemporal Alterations in Pediatric Bipolar Disorder. <i>Archives of General Psychiatry</i> , 2005, 62, 734.	12.3	240
83	Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. <i>Biological Psychiatry</i> , 2005, 57, 935-937.	1.3	250
84	Selective reduction in amygdala volume in pediatric anxiety disorders: A voxel-based morphometry investigation. <i>Biological Psychiatry</i> , 2005, 57, 961-966.	1.3	183
85	Reduced Serotonin Type 1A Receptor Binding in Panic Disorder. <i>Journal of Neuroscience</i> , 2004, 24, 589-591.	3.6	350
86	Neural and Behavioral Responses to Tryptophan Depletion in Unmedicated Patients With Remitted Major Depressive Disorder and Controls. <i>Archives of General Psychiatry</i> , 2004, 61, 765.	12.3	245
87	T1 ρ imaging using magnetization-prepared projection encoding (MaPPE). <i>Magnetic Resonance in Medicine</i> , 2000, 43, 421-428.	3.0	13